Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Stephen V Liu

Showing results (171-180 of 187) with videos related to

Pageof 19
Sort By:
Lancet (London, England)|June 5, 2025
Efficacy and safety of first-line maintenance therapy with lurbinectedin plus atezolizumab in extensive-stage small-cell lung cancer (IMforte): a randomised, multicentre, open-label, phase 3 trialLuis Paz-Ares, Hossein Borghaei, Stephen V Liu, et al.
JTO Clinical and Research Reports|January 6, 2025
Changing Treatment and Metastatic Disease Patterns in Patients with EGFR Mutated NSCLC: An Academic Thoracic Medical Investigator's Consortium Registry AnalysisMargaret Stalker, Connor B Grady, Alex Watts, et al.
Cancer Cell|February 17, 2024
Immune heterogeneity in small-cell lung cancer and vulnerability to immune checkpoint blockadeBarzin Y Nabet, Habib Hamidi, Myung Chang Lee, et al.
Lung Cancer (Amsterdam, Netherlands)|April 22, 2025
Osimertinib vs. Afatinib in 1L therapy of atypical EGFR-mutated metastatic non-small cell lung cancer (mNSCLC): A multi-institution, real-world survival analysisAdam Barsouk, Omar Elghawy, Alex Watts, et al.
JCO Precision Oncology|December 22, 2025
CRESTONE: A Phase II Study of the Efficacy and Safety of the HER3 Monoclonal Antibody, Seribantumab, in Solid Tumors With Neuregulin-1 (<i>NRG1</i>) FusionsTejas Patil, Jessica J Lin, Parneet K Cheema, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|June 23, 2019
Clinical Activity, Tolerability, and Long-Term Follow-Up of Durvalumab in Patients With Advanced NSCLCScott J Antonia, Ani Balmanoukian, Julie Brahmer, et al.
Lung Cancer (Amsterdam, Netherlands)|November 23, 2023
Disparities in outcomes between Black and White patients in North America with thoracic malignancies and COVID-19 infection (TERAVOLT)Laura Burns, Chih-Yuan Hsu, Jennifer G Whisenant, et al.
JCO Precision Oncology|February 9, 2022
<i>EGFR</i> Genotyping of Matched Urine, Plasma, and Tumor Tissue in Patients With Non-Small-Cell Lung Cancer Treated With Rociletinib, an <i>EGFR</i> Tyrosine Kinase InhibitorJonathan W Goldman, Chris Karlovich, Lecia V Sequist, et al.
JTO Clinical and Research Reports|November 14, 2025
Characteristics of Short-Term Survivors With <i>ALK</i> or <i>ROS1</i>-Altered Metastatic NSCLCKai-Lin Liu, Alex Watts, Connor B Grady, et al.
The New England Journal of Medicine|February 5, 2025
Efficacy of Zenocutuzumab in <i>NRG1</i> Fusion-Positive CancerAlison M Schram, Koichi Goto, Dong-Wan Kim, et al.
Pageof 19

Showing results (171-180 of 187) with videos related to

Sort By:
Pageof 19
Lancet (London, England)|June 5, 2025
Efficacy and safety of first-line maintenance therapy with lurbinectedin plus atezolizumab in extensive-stage small-cell lung cancer (IMforte): a randomised, multicentre, open-label, phase 3 trialLuis Paz-Ares, Hossein Borghaei, Stephen V Liu, et al.
JTO Clinical and Research Reports|January 6, 2025
Changing Treatment and Metastatic Disease Patterns in Patients with EGFR Mutated NSCLC: An Academic Thoracic Medical Investigator's Consortium Registry AnalysisMargaret Stalker, Connor B Grady, Alex Watts, et al.
Cancer Cell|February 17, 2024
Immune heterogeneity in small-cell lung cancer and vulnerability to immune checkpoint blockadeBarzin Y Nabet, Habib Hamidi, Myung Chang Lee, et al.
Lung Cancer (Amsterdam, Netherlands)|April 22, 2025
Osimertinib vs. Afatinib in 1L therapy of atypical EGFR-mutated metastatic non-small cell lung cancer (mNSCLC): A multi-institution, real-world survival analysisAdam Barsouk, Omar Elghawy, Alex Watts, et al.
JCO Precision Oncology|December 22, 2025
CRESTONE: A Phase II Study of the Efficacy and Safety of the HER3 Monoclonal Antibody, Seribantumab, in Solid Tumors With Neuregulin-1 (<i>NRG1</i>) FusionsTejas Patil, Jessica J Lin, Parneet K Cheema, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|June 23, 2019
Clinical Activity, Tolerability, and Long-Term Follow-Up of Durvalumab in Patients With Advanced NSCLCScott J Antonia, Ani Balmanoukian, Julie Brahmer, et al.
Lung Cancer (Amsterdam, Netherlands)|November 23, 2023
Disparities in outcomes between Black and White patients in North America with thoracic malignancies and COVID-19 infection (TERAVOLT)Laura Burns, Chih-Yuan Hsu, Jennifer G Whisenant, et al.
JCO Precision Oncology|February 9, 2022
<i>EGFR</i> Genotyping of Matched Urine, Plasma, and Tumor Tissue in Patients With Non-Small-Cell Lung Cancer Treated With Rociletinib, an <i>EGFR</i> Tyrosine Kinase InhibitorJonathan W Goldman, Chris Karlovich, Lecia V Sequist, et al.
JTO Clinical and Research Reports|November 14, 2025
Characteristics of Short-Term Survivors With <i>ALK</i> or <i>ROS1</i>-Altered Metastatic NSCLCKai-Lin Liu, Alex Watts, Connor B Grady, et al.
The New England Journal of Medicine|February 5, 2025
Efficacy of Zenocutuzumab in <i>NRG1</i> Fusion-Positive CancerAlison M Schram, Koichi Goto, Dong-Wan Kim, et al.
Pageof 19